Full history for every metric is available with a Kvantra account
Key financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | €bn | 36.3 | 37.1 | 21.3 | 21.1 | 21.8 | 22.9 | 23.4 | 23.8 |
| Operating profit | €bn | 2.18 | 2.25 | ||||||
| Net profit | €bn | 1.71 | 1.82 | 1.37 | -0.59 | 0.47 | 1.26 | 1.52 | 2.09 |
| EPS reported | € | 2.24 | 2.75 | ||||||
| Operating cashflow per share | € | 4.78 | 5.26 | ||||||
| Capex per share | € | 2.66 | 2.69 | ||||||
| FCF per share | € | 2.13 | 2.57 | ||||||
| Free cash flow | €bn | 1.20 | 1.45 | ||||||
| Net debt | €bn | 8.9 | 10.1 | ||||||
| Book value equity | €bn | 19.1 | 19.7 | ||||||
| Book value per share | € | 33.92 | 34.97 | ||||||
| Number of shares | m | 563.24 | 563.24 | ||||||
| DPS (TTM paid) | € | 1.05 | 1.05 |
Financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 21.87 | 15.40 | ||||||
| P/B LTM | x | 1.44 | 1.21 | ||||||
| P/S LTM | x | 1.21 | 1.02 | ||||||
| P/FCF LTM | x | 23.03 | 16.50 | ||||||
| EV/EBITDA LTM | x | 10.13 | 9.34 | ||||||
| EV/Sales LTM | x | 1.66 | 1.45 | ||||||
| Earnings Yield LTM | % | 4.57% | 6.49% | ||||||
| FCF Yield | % | 4.34% | 6.06% | ||||||
| Quality | |||||||||
| ROE | % | 6.62% | 7.89% | ||||||
| ROIC | % | 4.64% | 4.82% | ||||||
| Operating margin | % | 9.52% | 9.60% | ||||||
| Gross margin | % | 24.89% | 25.25% | ||||||
| FCF/Sales | % | 5.24% | 6.18% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +166.67% | +36.82% | ||||||
| Sales Growth YoY | % | +4.76% | +5.54% | ||||||
| Net Income Growth YoY | % | +168.37% | +35.29% | ||||||
| FCF Growth | % | -21.39% | +16.90% | ||||||
| Operating Profit Growth | % | +18.63% | +3.31% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 2.48% | 2.48% | ||||||
| Dividend Growth | % | +5.00% | +5.00% | ||||||
| Payout Ratio | % | 54.21% | 46.40% | ||||||
| FCF/Debt | x | 0.10 | 0.13 | ||||||
| Net Debt/EBITDA | x | 2.76 | 2.79 | ||||||
| EBIT/Net interest | x | 4.97 | 7.39 | ||||||
| Net debt/market cap | % | 32.40% | 42.50% | ||||||
| Net debt/Equity | x | 0.47 | 0.51 | ||||||
| Gross debt/equity | x | 0.62 | 0.58 | ||||||
ETFs that hold Fresenius
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| iShares DivDAX UCITS ETF (DE) | EXSB.DE | 10 | 3.43% |
| Deka DAXplus Maximum Dividend UCITS ETF | EL4X.DE | 10 | 4.59% |
Funds with Fresenius among their ten largest holdings, largest fund first.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Fresenius SE & Co. KGaA operates as a diverse healthcare enterprise, supplying a comprehensive array of products and services primarily focused on dialysis, hospital management, and outpatient medical care. Its activities are structured across four main divisions: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care division is dedicated to individuals living with chronic kidney failure, offering essential items like dialyzers, hemodialysis machines, and related disposable supplies, alongside various dialysis-specific services. Fresenius Kabi concentrates on the therapeutic treatment and care of ill patients. Its extensive product range includes intravenous pharmaceuticals, such as generic drugs for oncology, anesthetics, pain relief, anti-infectives, and critical care. Additionally, it provides parenteral and enteral nutritional products, infusion solutions, and blood volume expanders for infusion therapy. The segment also develops biosimilars—biological medicines for autoimmune and cancer conditions—and manufactures medical devices and disposables crucial for administering IV generics, infusion treatments, and clinical nutrition. Transfusion products for blood component collection and corporeal therapies are also part of its offerings. Fresenius Helios manages significant healthcare operations, encompassing 90 hospitals, approximately 130 outpatient clinics, and 6 prevention centers throughout Germany. In Spain, its presence includes 49 hospitals, 88 outpatient clinics, and around 300 risk prevention centers. This segment also delivers fertility treatment services through 33 clinics and an additional 39 sites located across 10 countries on three continents. Finally, the Fresenius Vamed division specializes in project management and service delivery for hospitals and other healthcare facilities. Its offerings span project development, meticulous planning, and turnkey construction solutions. Furthermore, it provides ongoing maintenance, technical oversight, and operational management services. The company, initially known as Fresenius SE, officially changed its name to Fresenius SE & Co. KGaA in January 2011. Founded in 1912, Fresenius SE & Co. KGaA maintains its corporate headquarters in Bad Homburg vor der Höhe, Germany.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Fresenius SE & Co. KGaA (FRE.DE)
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| iShares DivDAX UCITS ETF (DE) | EXSB.DE | 10 | 3.43% |
| Deka DAXplus Maximum Dividend UCITS ETF | EL4X.DE | 10 | 4.59% |
Funds with Fresenius among their ten largest holdings, largest fund first.
Based on consensus from external analysts. Not Kvantra's opinion.
Fresenius SE & Co. KGaA operates as a diverse healthcare enterprise, supplying a comprehensive array of products and services primarily focused on dialysis, hospital management, and outpatient medical care. Its activities are structured across four main divisions: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care division is dedicated to individuals living with chronic kidney failure, offering essential items like dialyzers, hemodialysis machines, and related disposable supplies, alongside various dialysis-specific services. Fresenius Kabi concentrates on the therapeutic treatment and care of ill patients. Its extensive product range includes intravenous pharmaceuticals, such as generic drugs for oncology, anesthetics, pain relief, anti-infectives, and critical care. Additionally, it provides parenteral and enteral nutritional products, infusion solutions, and blood volume expanders for infusion therapy. The segment also develops biosimilars—biological medicines for autoimmune and cancer conditions—and manufactures medical devices and disposables crucial for administering IV generics, infusion treatments, and clinical nutrition. Transfusion products for blood component collection and corporeal therapies are also part of its offerings. Fresenius Helios manages significant healthcare operations, encompassing 90 hospitals, approximately 130 outpatient clinics, and 6 prevention centers throughout Germany. In Spain, its presence includes 49 hospitals, 88 outpatient clinics, and around 300 risk prevention centers. This segment also delivers fertility treatment services through 33 clinics and an additional 39 sites located across 10 countries on three continents. Finally, the Fresenius Vamed division specializes in project management and service delivery for hospitals and other healthcare facilities. Its offerings span project development, meticulous planning, and turnkey construction solutions. Furthermore, it provides ongoing maintenance, technical oversight, and operational management services. The company, initially known as Fresenius SE, officially changed its name to Fresenius SE & Co. KGaA in January 2011. Founded in 1912, Fresenius SE & Co. KGaA maintains its corporate headquarters in Bad Homburg vor der Höhe, Germany.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free